Amarin
Corporation plc AMRN, a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health, announced today that it now has 30 patents issued or allowed by the
United States Patent and Trademark Office (USPTO) related to its flagship
product, Vascepa^® (icosapent ethyl) capsules.
Amarin recently received Notices of Allowance for U.S. Patent Application
Serial Numbers 13/777,398, 13/768,897, and 13/768,869, each titled "Stable
Pharmaceutical Composition and Methods of Using Same." The scope of coverage
related to Vascepa represented by these applications is the broadest allowed
to date.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in